- Home
- EIC vs ATXS Comparison
EIC vs ATXS Comparison
Compare EIC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- ATXS
- Stock Information
- Founded
- EIC N/A
- ATXS 2008
- Country
- EIC United States
- ATXS United States
- Employees
- EIC N/A
- ATXS N/A
- Industry
- EIC Finance/Investors Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- ATXS Health Care
- Exchange
- EIC Nasdaq
- ATXS Nasdaq
- Market Cap
- EIC 343.8M
- ATXS 401.2M
- IPO Year
- EIC 2019
- ATXS 2015
- Fundamental
- Price
- EIC $12.76
- ATXS $6.56
- Analyst Decision
- EIC Strong Buy
- ATXS Buy
- Analyst Count
- EIC 1
- ATXS 6
- Target Price
- EIC $17.50
- ATXS $32.00
- AVG Volume (30 Days)
- EIC 349.9K
- ATXS 233.1K
- Earning Date
- EIC 08-12-2025
- ATXS 08-11-2025
- Dividend Yield
- EIC 18.87%
- ATXS N/A
- EPS Growth
- EIC N/A
- ATXS N/A
- EPS
- EIC 0.55
- ATXS N/A
- Revenue
- EIC $51,224,692.00
- ATXS N/A
- Revenue This Year
- EIC $37.84
- ATXS N/A
- Revenue Next Year
- EIC $23.33
- ATXS N/A
- P/E Ratio
- EIC $23.06
- ATXS N/A
- Revenue Growth
- EIC 68.61
- ATXS N/A
- 52 Week Low
- EIC $12.46
- ATXS $3.56
- 52 Week High
- EIC $16.71
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- EIC 36.69
- ATXS 55.85
- Support Level
- EIC $12.90
- ATXS $6.31
- Resistance Level
- EIC $13.15
- ATXS $7.34
- Average True Range (ATR)
- EIC 0.29
- ATXS 0.36
- MACD
- EIC -0.05
- ATXS -0.01
- Stochastic Oscillator
- EIC 24.39
- ATXS 44.29
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.